Romania approves AirFluSal Forspiro

Romania has approved the 50 µg/500 µg dose version of Sandoz’s AirFluSal Forspiro salmeterol/fluticasone DPI for the treatment of asthma and COPD, triggering a €1.5 million milestone payment to Vectura. The inhaler has also been approved recently by Denmark, Germany, Sweden, and Hungary.

Read the Sandoz press release.

Share

published on

May 10-May 14RDD 2026, Phoenix, AZ, USA

May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA

May 17-May 20: ATS International Conference 2026, Orlando, FL, USA

June 10SMI.London 2026, London, UK

July 13-July 162026 ISAM Congress, Taipei, Taiwan